Acdima signs MoU with SK Plasma to produce plasma-derived products

Acdima Pharma signed an MoU with South Korea’s SK Plasma to produce plasma-derived medicinal products in Egypt, the local press reports, without providing additional details. Medical centers treating covid-19 have been experimenting with plasma therapy, administering antibody-rich blood from recovered patients to new ones through transfusions.